Biotech leader brings deep experience scaling life science companies and will support Aspect’s growth and therapeutic pipeline advancement
Vancouver, BC, Canada – May 28, 2025 – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today announced the appointment of Andrew Booth to its Board of Directors.
"We’re thrilled to welcome Andrew Booth to Aspect’s Board of Directors," said Tamer Mohamed, Founder and CEO, Aspect Biosystems. "Andrew brings decades of experience scaling high-impact organizations and has played a pivotal role in the growth of globally relevant companies within Canada’s life sciences sector. His insights and perspectives will be invaluable as we advance our pipeline and build a generational biotech company with the potential to transform the lives of people with serious diseases."
Andrew Booth is currently the Chief Financial Officer (CFO) at AbCellera, a biotechnology company that discovers and develops antibody medicines. He served on AbCellera’s Board of Directors for nearly four years before joining as CFO in 2019. As CFO, Andrew played a key role in taking the company public on the Nasdaq in 2020. Prior to AbCellera, Andrew spent 10 years at STEMCELL Technologies, where he held roles as CFO and Chief Commercial Officer. Earlier in his career, he spent seven years at General Electric, concluding as Head of M&A and Business Development for GE Healthcare’s Europe, Middle East, and Africa business and its global Life Sciences business. He was also formerly the Chairman of the Board of Precision Nanosystems, acquired by Danaher in 2021. Andrew holds an MBA from INSEAD and a BASc in Engineering Physics from the University of British Columbia.
"It's a privilege to join Aspect's Board of Directors and support its groundbreaking work in bioprinted tissue therapeutics," said Andrew Booth. "I look forward to working with Aspect's leadership team to advance its mission, bring the benefits of this new modality to patients, and help grow and scale a great Vancouver-based biotechnology company."
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of bioprinted tissue therapeutics across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity. For more information, please visit www.aspectbiosystems.com and follow on LinkedIn.
Contact
Natalie Korenic
Aspect Biosystems
media@aspectbiosystems.com